Evaluation of Hypertension as a Marker of Bevacizumab Efficacy
- 80 Downloads
Predictive factors for efficacy of vascular endothelial growth factor pathway-targeted therapies have not been identified or confirmed. Hypertension has been observed as a side effect to anti-vascular endothelial growth factor therapy. The goal of our study was to retrospectively assess if hypertension induced during treatment with bevacizumab was associated with clinical outcome in metastatic colorectal cancer patients treated with bevacizumab.
Patients and methods
We conducted a retrospective chart review of patients with colorectal cancer treated with bevacizumab at Lombardi Comprehensive Cancer Center from 2004 to 2008.
Eighty-four patients with metastatic colorectal cancer were eligible. Eighteen patients (21%) developed grades 3 hypertension. Twelve patients (14%) developed grade 2 hypertension. Six patients (7%) developed grade 1 hypertension. Median overall survival (OS) was 29 months and progression-free survival (PFS) was 10 months. Patients with any grade hypertension while on bevacizumab had an adjusted hazard ratio for death of 0.32 (p = 0.03) and adjusted risk of progression of 51% (p = 0.02) compared to those without hypertension (HTN). When stratified by metastatic disease, patients presenting with metastases who developed HTN had better OS and PFS (p = 0.03 and 0.01.) Among patients without metastases at diagnosis, those with HTN on bevacizumab had better OS and PFS but results were not statistically significant (p = 0.60 and 0.62, respectively).
Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving bevacizumab.
Keywordsbevacizumab colorectal cancer hypertension
- 6.Giantonio BJ, Catalano PJ, Meropol N, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.CrossRefPubMedGoogle Scholar
- 12.Veronese ML, Flaherty KT, Townsend R, et al. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: mechanisms of hypertension. J Clin Oncol. 2004;14(22 Suppl):2035.Google Scholar
- 14.Hood JD, Meininger CJ, Ziche M, Grander HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol. 1998;274:H1054–H58.Google Scholar
- 18.Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: A multinational, randomized, double-blinded phase III study in 2nd line patients with metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo. J Clin Oncol. 2007;18(25 Suppl):4033.Google Scholar
- 20.Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2005;16(23 Suppl):2.Google Scholar
- 21.Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol. 2005;16(23 Suppl):3.Google Scholar
- 22.Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRite). J Clin Oncol. 2006;18(24 Suppl):3537.Google Scholar
- 23.Berry S, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for metastatic colorectal cancer—first B E A trial. J Clin Oncol. 2006;18(24 Suppl):3534.Google Scholar